Clinical Trials


Taste Properties of HIV Inhibitor

This study has been terminated
Bristol-Myers Squibb

Senopsys, LLC

Information provided by (Responsible Party)
Bristol-Myers Squibb Identifier

First received: November 17, 2015
Last updated: May 11, 2016
Last Verified: May 2016
History of Changes


The purpose of the study is to assess the taste properties of HIV inhibitor

Condition Intervention Phase
Combination Therapy HIV/AIDS

Drug : BMS-955176
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures

  • Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria [ Time Frame: Up to 2 years ]

Enrollment: 6
Study Start Date: November 2015
Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: BMS-955176
BMS-955176 specified dose on specified days
Drug: BMS-955176
Other Name: HIV Maturation Inhibitor


Ages Eligible for Study: 25 Years to 80 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  


For more information regarding BMS clinical trial participation, please visit
Inclusion Criteria:

  • Men and women of non-childbearing potential professional sensory panelists
  • Aged between 25 and 80 years

Exclusion Criteria:
  • History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
  • Positive HIV test

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02608918


United States, Massachusetts
Senopsys Llc
Woburn, Massachusetts, United States, 01801

Sponsors and Collaborators

Bristol-Myers Squibb
Senopsys, LLC


Study Director: Bristol Myers Squibb Bristol-Myers Squibb
More Information

More Information

Additional Information:

BMS Clinical Trial Information

Additional Information:

BMS clinical trial educational resource

Additional Information:

Investigator Inquiry form

Additional Information:

FDA Safety Alerts and Recalls

Responsible Party: Bristol-Myers Squibb Identifier: NCT02608918   History of Changes  
Other Study ID Numbers: AI468-065  
Study First Received: November 17, 2015  
Last Updated: May 11, 2016 processed this data on March 21, 2018
This information is provided by